Tesamorelin Acetate Patent Expiration

Tesamorelin Acetate is used for reducing excess abdominal fat in HIV-infected patients with lipodystrophy. It was first introduced by Emd Serono Inc in its drug Egrifta on Nov 10, 2010.


Tesamorelin Acetate Patents

Given below is the list of patents protecting Tesamorelin Acetate, along with the drug name that holds that patent and the company name owning that drug.

Drug Used in Drug Patent Number Drug Patent Title Drug Patent Expiry Drug Owner
Egrifta US7316997 GH secretagogues and uses thereof Aug 14, 2023

(Expired)

Emd Serono
Egrifta US8314066 GH secretagogues and uses thereof Aug 14, 2023

(Expired)

Emd Serono
Egrifta US8435945 GH secretagogues and uses thereof Aug 14, 2023

(Expired)

Emd Serono
Egrifta US7144577 Treatment of HIV-associated dysmorphia/dysmetabolic syndrome (HADDS) with or without lipodystrophy Jul 14, 2020

(Expired)

Emd Serono
Egrifta US5861379 Chimeric fatty body-pro-GRF analogs with increased biological potency May 26, 2015

(Expired)

Emd Serono
Egrifta US6020311 GRF analogs with increased biological potency May 26, 2015

(Expired)

Emd Serono



Tesamorelin Acetate's Family Patents

Family Patents

Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List